Ocumetics Technology Corp (TSE:OTC) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ocumetics Technology Corp has successfully completed the second tranche of its debenture private placement, raising CA$940,000 in net proceeds, which will predominantly fund its inaugural human clinical trials and ongoing R&D. The offering has reached its goal of CA$4 million, with the debentures carrying an 18% annual interest rate and being convertible into common shares at $0.32 each. The funds allocation may adapt to the company’s operational needs and emerging opportunities.
For further insights into TSE:OTC stock, check out TipRanks’ Stock Analysis page.